![\"Anxiety:](\"https:\/\/c.media-amazon.com\/images\/I\/71qVXP7Nz3L._SY466_.jpg\" "\\"\\"")
\n <\/a>\n <\/div>\n \n Anxiety: The Silent Epidemic of the 21st Century by Augusto Cury, PhD<\/h2>\n
Confira este produto especial!<\/p>\n \n Buy here, now!!! <\/a>\n <\/div>\n <\/div>\n \n\n\n These are stimulant medications that work by increasing the availability of key neurotransmitters like dopamine and norepinephrine in the brain. This action is believed to enhance attention, impulse control, and reduce hyperactivity, positively impacting executive function in adults with Attention Deficit Hyperactivity Disorder . The review included:<\/p>\n Dextroamphetamine:<\/strong> A specific type of amphetamine.<\/p>\n<\/li>\n Lisdexamfetamine (e.g., Vyvanse\u00ae):<\/strong> A prodrug that converts into dextroamphetamine in the body, typically offering extended-release action.<\/p>\n<\/li>\n Mixed Amphetamine Salts (MAS) (e.g., Adderall\u00ae):<\/strong> A combination of different amphetamine salts, available in immediate or extended-release formulations.<\/p>\n<\/li>\n<\/ul>\n Also read: ADHD and the Art of Thinking Fast and Slow<\/a><\/em><\/strong><\/p>\n\n The short answer: Yes, in the short term\u2014but with important reservations about evidence quality.<\/p>\n Symptom Improvement:<\/strong> The review found that amphetamines, particularly lisdexamfetamine and MAS, were more effective than placebo in reducing ADHD symptom severity, according to both clinicians and patients. Lisdexamfetamine showed clear benefits for adult Attention Deficit Hyperactivity Disorder . However, evidence for dextroamphetamine alone was less convincing in clinician assessments, raising questions when comparing lisdexamfetamine to dextroamphetamine.<\/p>\n<\/li>\n Evidence Quality:<\/strong> It\u2019s crucial to highlight that the authors rated the overall evidence as low to very low. Also read: ADHD and the Art of Thinking Fast and Slow<\/a><\/em><\/strong><\/p>\n\n The findings here were less encouraging. Amphetamines did not show improved treatment retention compared to placebo\u2014meaning patients were no more likely to stay on medication over time.<\/p>\n Safety remains a key concern with ADHD stimulants. The review highlighted:<\/p>\n Higher Dropout Rates Due to Side Effects:<\/strong> Adults taking amphetamines were more likely to discontinue treatment because of adverse effects.<\/p>\n<\/li>\n Common Side Effects:<\/strong> Although not detailed extensively, typical amphetamine side effects include insomnia, appetite loss, dry mouth, anxiety, irritability, headaches, nausea, elevated blood pressure, and increased heart rate.<\/p>\n<\/li>\n Cardiovascular Risk:<\/strong> The review found no significant difference between amphetamines and placebo regarding cardiovascular-related dropouts. However, due to short-term data and low-quality evidence, long-term risks remain uncertain.<\/p>\n<\/li>\n<\/ul>\n Also read: ADHD and the Art of Thinking Fast and Slow<\/a><\/em><\/strong><\/p>\n\n Other Key Findings from the Cochrane Review on ADHD and Amphetamines<\/strong><\/p>\n Dosage:<\/strong> Higher doses did not prove to be more effective.<\/p>\n<\/li>\n Release Type:<\/strong> No clear differences were found between immediate and extended-release formulations regarding efficacy or safety.<\/p>\n<\/li>\n Comorbidities:<\/strong> The presence of mild anxiety, depression, or substance abuse history didn\u2019t significantly alter amphetamine effectiveness in the limited studies available. However, more research is needed, especially for adults with complex comorbidities.<\/p>\n<\/li>\n Comparison to Other Medications:<\/strong> Few studies compared amphetamines to alternatives like guanfacine, modafinil, or paroxetine\u2014insufficient data to draw conclusions.<\/p>\n<\/li>\n Anxiety and Depression:<\/strong> It remains unclear how amphetamines impact anxiety or depressive symptoms, as most studies excluded patients with severe comorbid conditions.<\/p>\n<\/li>\n<\/ul>\n Also read: ADHD and the Art of Thinking Fast and Slow<\/a><\/em><\/strong><\/p>\n\n This Cochrane systematic review confirms that stimulants like Vyvanse\u00ae and Adderall\u00ae can reduce Attention Deficit Hyperactivity Disorder symptoms in adults over the short term. However, this benefit comes with a higher risk of side effects, increased treatment dropout rates, and no guarantee of long-term adherence.<\/p>\n Moreover, the overall quality of research is still considered low, mainly due to short study durations. Long-term effects, especially in individuals with complex comorbidities, remain poorly understood.<\/p>\n Have an Open Conversation with Your Doctor:<\/strong> ADHD treatment with amphetamines should be personalized, carefully weighing benefits against potential risks and side effects.<\/p>\n<\/li>\n Consider All Options:<\/strong> Amphetamines are one tool among many. Discuss other ADHD medications (like methylphenidate or non-stimulants), therapy (such as CBT), and lifestyle adjustments.<\/p>\n<\/li>\n Monitor Your Response:<\/strong> If starting treatment, stay attentive to how you feel and communicate regularly with your healthcare provider.<\/p>\n<\/li>\n Set Realistic Expectations:<\/strong> Medication is helpful but works best as part of a comprehensive ADHD management plan.<\/p>\n<\/li>\n<\/ul>\n Amphetamines can be valuable for many adults with Attention Deficit Hyperactivity Disorder , but informed decisions\u2014grounded in science and guided by professional advice\u2014are essential.<\/p>\n Important:<\/em> This content is informational and based on scientific review. Never start, stop, or change your medication without medical guidance.<\/p>\n Also read: ADHD and the Art of Thinking Fast and Slow<\/a><\/em><\/strong><\/p>\n\n Bobbie Goods Postcard Coloring Book combines creativity and connection in a delightful collection of pullout postcards.<\/p>\n \n Buy here, now!!! <\/a>\n <\/div>\n <\/div>\n \n\n\n\n Author:<\/strong> Xavier Castells<\/a><\/p>\n\n\n\n Sorce:<\/strong>\u00a0Affiliations<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n<\/div><\/div>\n\n\n\n Original Research:\u00a0<\/strong>Oepn acessesWhat Are the Amphetamines Used for ADHD?<\/strong><\/h2>\n
![\"\"](\"https:\/\/tdah.world\/en\/wp-content\/uploads\/2025\/04\/pexels-karolina-grabowska-4046996-1-scaled.jpg\" "\\"\\"")
<\/p>\n\n
Do They Work to Reduce ADHD Symptoms in Adults? (Amphetamine Effectiveness)<\/strong><\/h2>\n
\n
Why? Mainly due to challenges in maintaining blinding (patients and doctors might guess who\u2019s on active medication due to noticeable stimulant effects), high dropout rates, and short study durations (averaging just 5 weeks). These factors limit conclusions about long-term safety.<\/p>\n<\/li>\n<\/ul>\nWhat About Staying on Treatment (Adherence\/Retention)?<\/strong><\/h2>\n
Are They Safe? Risks and Benefits of Amphetamines for ADHD<\/strong><\/h3>\n
\n
\n
Conclusion: Amphetamines Can Help, But Require Caution and Open Discussion<\/strong><\/h2>\n
What Should You Do With This Information?<\/strong><\/h3>\n
\n
![\"Bobbie](\"https:\/\/c.media-amazon.com\/images\/I\/71Vj09Usi9L._SX445_.jpg\" "\\"\\"")
\n <\/a>\n <\/div>\n \n Bobbie Goods<\/h2>\n
References<\/h6><\/li>
Learn More<\/h6><\/li><\/ul><\/div>
\u201cAmphetamines for attention deficit hyperactivity disorder (ADHD) in adults<\/a>” Xavier Castells<\/a> et. al Affiliations<\/p>\n<\/div><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\nFAQ \u2014 Amphetamines for Adult ADHD: Effectiveness, Safety, and Key Insights<\/strong>
<\/strong><\/h2>\n\n\n